Impact UK Location: Harlow

REF impact found 4 Case Studies

Currently displayed text from case study:

Catching the Drug Cheats: The Science Behind Anti-Doping for the London 2012 Olympic and Paralympic Games

Summary of the impact

King's College London (KCL), operating a state-of-the-art Drug Control Centre (DCC) in collaboration with GlaxoSmithKline (GSK), delivered the anti-doping analysis at the London 2012 Olympic and Paralympic Games. This operation, undertaken in their World Anti-Doping Agency's (WADA) accredited laboratories, was characterised by unprecedented scale, speed and accuracy. It succeeded in protecting the health of athletes and the integrity of the Games. KCL was chosen to undertake the 24/7 anti-doping operation based on its cutting-edge bio-analytical research in drug control. Although a number of athletes were disqualified in the pre-Games testing, the deterrent effect of the KCL work was evidenced by the few doping cases during the Games itself. Using the new biomarker test developed by the DCC at KCL in collaboration with colleagues at the University of Southampton, the team identified for the first time the administration of recombinant human growth hormone (hGH) in two athletes. The findings of the KCL-led operation are already being used to develop similar testing facilities for the 2016 Olympic Games in Rio de Janeiro and have opened up the science of drug-testing to schools through the "Scientists in Sport" initiative.

Submitting Institution

King's College London

Unit of Assessment

Sport and Exercise Sciences, Leisure and Tourism

Summary Impact Type

Societal

Research Subject Area(s)

Chemical Sciences: Analytical Chemistry
Medical and Health Sciences: Clinical Sciences, Pharmacology and Pharmaceutical Sciences

C1 - The Founding of Argenta Discovery and Pulmagen Therapeutics

Summary of the impact

The growth and performance of Biofocus Galapagos Argenta (BGA) and Pulmagen Therapeutics (PT) are underpinned by research from the Imperial-based TeknoMed project that started in 1997. BGA was formed in 2010 through the acquisition of Argenta Discovery (AD) by Biofocus Galapagos for €16.5 million and is one of the world's largest drug discovery service organisations with 390 plus employees and turnover of €135 million [section 5, A]. PT was formed as a separate company to own the complete AD drug pipeline. It develops new medicines to treat asthma, cystic fibrosis and allergic diseases. In 2011 BGA signed agreements with PT for an initial £6million fee and with Genentech for £21.5million.

Submitting Institution

Imperial College London

Unit of Assessment

Chemistry

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Inorganic Chemistry, Organic Chemistry, Other Chemical Sciences

Raised awareness and more effective interventions in Children with Speech Language Impairment.

Summary of the impact

Research has produced an Interim impact on Speech and Language Therapists (SLTs) and Specialist Teachers who work with Children with Language difficulties. I-CAN, a major children's communication charity, embraced the research findings and associated resources to support their involvement in a nationwide study on pupils at risk of fixed-term or permanent exclusion.

Key findings from the study revealed that 90% of SLTs would change the way they would work; over 80% of pupils improved their confidence, behaviour and communication skills; 95% of parents reported an improvement in attendance; and fixed-term exclusions decreased by 21%.

Submitting Institution

London South Bank University

Unit of Assessment

Psychology, Psychiatry and Neuroscience

Summary Impact Type

Societal

Research Subject Area(s)

Medical and Health Sciences: Clinical Sciences, Public Health and Health Services
Psychology and Cognitive Sciences: Psychology

Redesigning children’s growth charts

Summary of the impact

Research at the UCL Institute of Child Health underpinned the update in 2009 of children's growth charts, which allow for more accurate determination of a child's growth pattern and provide better tools for assessing possible weight problems in children. The new charts are now in universal use in the UK for children from birth to 18 years of age, including preterm babies. Having been quickly adopted, they now account for 90% of all growth chart sales. Modified versions of the charts are in use in Ireland and New Zealand. In the UK they are provided to all new parents as part of the Personal Child Health Record (PCHR) — known as the "red book". They are used in general practice, community paediatrics, general paediatrics and paediatric endocrinology. The most recent charts are for use in children with growth or nutritional problems.

Submitting Institution

University College London

Unit of Assessment

Public Health, Health Services and Primary Care

Summary Impact Type

Health

Research Subject Area(s)

Medical and Health Sciences: Public Health and Health Services

Filter Impact Case Studies

Download Impact Case Studies